Related Experiment Video
Updated: Aug 5, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Development of the First YTHDC1 Degrader with Improved Antileukemia Activity
Zhongpao Xie1, Yuanyuan Zhang1, Weicai Song1
1State Key Laboratory of Metabolism and Regulation in Complex Organisms, Key Laboratory of Biomedical Polymers of Ministry of Education, Hubei Province Key Laboratory of Allergy and Immunology, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China.
Researchers developed XY-2, the first PROTAC molecule targeting YTHDC1, to treat acute myeloid leukemia (AML). This novel degrader effectively eliminates YTHDC1, inhibiting cancer cell growth and offering a promising new therapeutic strategy for AML patients.
Area of Science:
- Molecular Biology
- RNA Modifications
- Cancer Therapeutics
Background:
- N⁶-Methyladenosine (m⁶A) is the most common internal modification in eukaryotic mRNA.
- YTHDC1 is a key nuclear reader protein involved in acute myeloid leukemia (AML).
- Targeted degradation of YTHDC1 for AML therapy remains unexplored.
Purpose of the Study:
- To design and synthesize the first PROTAC molecule targeting YTHDC1.
- To evaluate the therapeutic efficacy of YTHDC1 degradation in AML models.
- To investigate the molecular mechanisms underlying XY-2's anti-leukemic effects.
Main Methods:
- Rational design and synthesis of a YTHDC1-targeting PROTAC (XY-2) based on cocrystal structure.
- Assessment of YTHDC1 degradation efficiency using nanomolar concentrations in AML cell lines (MOLM13, Kasumi-1).
- Evaluation of XY-2's functional effects on AML cell proliferation, migration, invasion, and apoptosis, alongside transcriptomic and mechanistic analyses.
Main Results:
- XY-2 induced efficient proteasome-dependent degradation of YTHDC1 at low nanomolar concentrations (DC₅₀ values ~11-13 nM).
- XY-2 significantly inhibited AML cell proliferation, migration, and invasion, while promoting apoptosis, outperforming the parent inhibitor.
- Transcriptomic analysis revealed XY-2 downregulated genes involved in cell cycle, DNA replication, and mitosis, causing G1 phase arrest.
Conclusions:
- XY-2 is the first highly efficient YTHDC1 degrader.
- Targeted degradation of YTHDC1 represents a potent and promising therapeutic strategy for AML.
- XY-2 demonstrates significant anti-leukemic activity through cell cycle regulation.
